TEDCO recently launched ‘TEDCO Talks’, a series featuring thought leaders in economic development across the State of Maryland. On May 28th, TEDCO CEO & Executive Director, Troy LeMaile-Stovall interviewed Sally Allain, Head of JLABS @ Washington DC, about the future of the innovation ecosystem and the crucial role that JLABS will play in advancing the BioHealth Capital Region.
The Children’s National Research & Innovation Campus with Johnson & Johnson Innovation – JLABS @ Washington, DC A Site Built for Research & Development Advancement
Set on the historic Walter Reed Army Medical Center, the Children’s National Research & Innovation Campus will be a one-of-kind innovation hub. The nearly 12-acre campus will house leading entrepreneurs, [….]
The new hub, dubbed JLABS @ Washington, D.C., will host up to 50 startups spanning pharmaceuticals, medical devices, consumer and health tech companies, including those working on pediatric care. The first group of companies moving in include spinouts from the Children’s National Health System, J&J’s partner in running the site, startups local to the D.C. area and those from other parts of the country.
For entrepreneurs and early stage companies, raising capital can be challenging. For female entrepreneurs it can be even more challenging as they can experience gender bias in their efforts to [….]
Expanding the mechanisms for administering therapeutics and vaccines may have the potential to disrupt the status quo and improve availability and accessibility of therapeutic and preventive treatments. This session will [….]
5 Questions with Rachel Rath, MBA, MPH, Director, BARDA Alliance for Johnson & Johnson Innovation, JLABS @ Washington, DC
Rachel is the Director of the BARDA Alliance for Johnson & Johnson Innovation, based at JLABS @ Washington, DC. In this role, she is responsible for managing the BLUE KNIGHT™ collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA). BLUE KNIGHT™ focuses on addressing public-health threats and emerging infectious diseases by supporting companies with emerging science and technology solutions that aim to improve health security and responses.
2020 found the United States embroiled in a chaotic political environment, reckoning with social unrest and racial injustice, and voting in one of the most consequential presidential elections in the country’s history.
In seeking to combat emerging infectious diseases and other 21st-century health threats, the path to better prepared, protected, and healthy individuals, families, and communities could rely on unlocking the collective power of the global community. BLUE KNIGHT™ seeks to answer this call.
Approximately 300,000 children from infancy to age 14 are diagnosed with cancer worldwide every year . Although cure rates for some pediatric cancers have increased to about 80% in recent [….]
U.S. Black consumers spend $1.2 trillion annually, with shoppers spending an estimated $127 million on grooming aids and $465 million on skin care. However, according to the Census Bureau only [….]